Literature DB >> 32540874

Delays in referral from primary care worsen survival for patients with colorectal cancer: a retrospective cohort study.

Chanpreet S Arhi1, Elaine M Burns1, Alex Bottle2, George Bouras1, Paul Aylin2, Paul Ziprin1, Ara Darzi1.   

Abstract

BACKGROUND: Delays in referral for patients with colorectal cancer may occur if the presenting symptom is falsely attributed to a benign condition. AIM: To investigate whether delays in referral from primary care are associated with a later stage of cancer at diagnosis and worse prognosis. DESIGN AND
SETTING: A national retrospective cohort study in England including adult patients with colorectal cancer identified from the cancer registry with linkage to Clinical Practice Research Datalink, who had been referred following presentation to their GP with a 'red flag' or 'non-specific' symptom.
METHOD: The hazard ratios (HR) of death were calculated for delays in referral of between 2 weeks and 3 months, and >3 months, compared with referrals within 2 weeks.
RESULTS: A total of 4527 (63.5%) patients with colon cancer and 2603 (36.5%) patients with rectal cancer were included in the study. The percentage of patients presenting with red-flag symptoms who experienced a delay of >3 months before referral was 16.9% of those with colon cancer and 13.5% of those with rectal cancer, compared with 35.7% of patients with colon cancer and 42.9% of patients with rectal cancer who presented with non-specific symptoms. Patients referred after 3 months with red-flag symptoms demonstrated a significantly worse prognosis than patients who were referred within 2 weeks (colon cancer: HR 1.53; 95% confidence interval [CI] = 1.29 to 1.81; rectal cancer: HR 1.30; 95% CI = 1.06 to 1.60). This association was not seen for patients presenting with non-specific symptoms. Delays in referral were associated with a significantly higher proportion of late-stage cancers.
CONCLUSION: The first presentation to the GP provides a referral opportunity to identify the underlying cancer, which, if missed, is associated with a later stage in diagnosis and worse survival. © British Journal of General Practice 2020.

Entities:  

Keywords:  cancer; colorectal cancer; delays; primary care; referral; stage; survival

Mesh:

Year:  2020        PMID: 32540874      PMCID: PMC7299547          DOI: 10.3399/bjgp20X710441

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  47 in total

1.  The impact of the two-week wait referral pathway on rectal cancer survival.

Authors:  A C Currie; J Evans; N J Smith; G Brown; A M Abulafi; R I Swift
Journal:  Colorectal Dis       Date:  2012-07       Impact factor: 3.788

2.  Diagnostic interval and mortality in colorectal cancer: U-shaped association demonstrated for three different datasets.

Authors:  Marie Louise Tørring; Morten Frydenberg; William Hamilton; Rikke P Hansen; Marianne D Lautrup; Peter Vedsted
Journal:  J Clin Epidemiol       Date:  2012-03-27       Impact factor: 6.437

3.  Therapeutic delay reduces survival of rectal cancer but not of colonic cancer.

Authors:  L H Iversen; S Antonsen; S Laurberg; M D Lautrup
Journal:  Br J Surg       Date:  2009-10       Impact factor: 6.939

4.  Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets.

Authors:  L Elliss-Brookes; S McPhail; A Ives; M Greenslade; J Shelton; S Hiom; M Richards
Journal:  Br J Cancer       Date:  2012-09-20       Impact factor: 7.640

5.  The mortality of colorectal cancer in relation to the initial symptom at presentation to primary care and to the duration of symptoms: a cohort study using medical records.

Authors:  S Stapley; T J Peters; D Sharp; W Hamilton
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

6.  Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study.

Authors:  Henrik Møller; Carolynn Gildea; David Meechan; Greg Rubin; Thomas Round; Peter Vedsted
Journal:  BMJ       Date:  2015-10-13

7.  A comparison of the recording of comorbidity in primary and secondary care by using the Charlson Index to predict short-term and long-term survival in a routine linked data cohort.

Authors:  C J Crooks; J West; T R Card
Journal:  BMJ Open       Date:  2015-06-05       Impact factor: 2.692

8.  Do colorectal cancer patients diagnosed as an emergency differ from non-emergency patients in their consultation patterns and symptoms? A longitudinal data-linkage study in England.

Authors:  C Renzi; G Lyratzopoulos; T Card; T P C Chu; U Macleod; B Rachet
Journal:  Br J Cancer       Date:  2016-08-18       Impact factor: 7.640

9.  The CAPER studies: five case-control studies aimed at identifying and quantifying the risk of cancer in symptomatic primary care patients.

Authors:  W Hamilton
Journal:  Br J Cancer       Date:  2009-12-03       Impact factor: 7.640

10.  Comparison of cancer diagnostic intervals before and after implementation of NICE guidelines: analysis of data from the UK General Practice Research Database.

Authors:  R D Neal; N U Din; W Hamilton; O C Ukoumunne; B Carter; S Stapley; G Rubin
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

View more
  8 in total

1.  Mode of Referral of Ovarian Cancer Patients: Does it Alter Treatment and Survival?

Authors:  Anas Barakat; Aemn Ismail; Quentin Davies; Supratik Chattopadhyay
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

2.  Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?

Authors:  Sara Benitez Majano; Georgios Lyratzopoulos; Bernard Rachet; Niek J de Wit; Cristina Renzi
Journal:  Br J Cancer       Date:  2021-11-05       Impact factor: 9.075

3.  Prolonged Diagnostic Intervals as Marker of Missed Diagnostic Opportunities in Bladder and Kidney Cancer Patients with Alarm Features: A Longitudinal Linked Data Study.

Authors:  Yin Zhou; Fiona M Walter; Hardeep Singh; William Hamilton; Gary A Abel; Georgios Lyratzopoulos
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

4.  Risk prediction models for symptomatic patients with bladder and kidney cancer: a systematic review.

Authors:  Hannah Harrison; Juliet A Usher-Smith; Lanxin Li; Lydia Roberts; Zhiyuan Lin; Rachel E Thompson; Sabrina H Rossi; Grant D Stewart; Fiona M Walter; Simon Griffin; Yin Zhou
Journal:  Br J Gen Pract       Date:  2021-12-31       Impact factor: 5.386

Review 5.  Interventions to improve early cancer diagnosis of symptomatic individuals: a scoping review.

Authors:  George N Okoli; Otto L T Lam; Viraj K Reddy; Leslie Copstein; Nicole Askin; Anubha Prashad; Jennifer Stiff; Satya Rashi Khare; Robyn Leonard; Wasifa Zarin; Andrea C Tricco; Ahmed M Abou-Setta
Journal:  BMJ Open       Date:  2021-11-09       Impact factor: 2.692

6.  Relationship between time from symptom's onset to diagnosis and prognosis in patients with symptomatic colorectal cancer.

Authors:  Magdalena Esteva; Alfonso Leiva; María Ramos-Monserrat; Alejandro Espí; Luis González-Luján; Francesc Macià; Cristiane Murta-Nascimento; María A Sánchez-Calavera; Rosa Magallón; Vanesa Balboa-Barreiro; Teresa Seoane-Pillado; Sonia Pertega-Díaz
Journal:  BMC Cancer       Date:  2022-08-22       Impact factor: 4.638

7.  Faecal immunochemical test: challenges and opportunities for cancer diagnosis in primary care.

Authors:  Mary Craig; Jeff Turner; Jared Torkington; Tom Crosby
Journal:  Br J Gen Pract       Date:  2022-07-28       Impact factor: 6.302

8.  Influence of Diagnostic Delay on Survival Rates for Patients with Colorectal Cancer.

Authors:  María Padilla-Ruiz; María Morales-Suárez-Varela; Francisco Rivas-Ruiz; Julia Alcaide; Esperanza Varela-Moreno; Irene Zarcos-Pedrinaci; Teresa Téllez; Nerea Fernández-de Larrea-Baz; Marisa Baré; Amaia Bilbao; Cristina Sarasqueta; Urko Aguirre-Larracoechea; José María Quintana; Maximino Redondo
Journal:  Int J Environ Res Public Health       Date:  2022-03-18       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.